These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27521362)

  • 61. Vaccination against cytomegalovirus.
    Plotkin SA
    Arch Virol Suppl; 2001; (17):121-34. PubMed ID: 11339541
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development of novel vaccines against human cytomegalovirus.
    Cui X; Snapper CM
    Hum Vaccin Immunother; 2019; 15(11):2673-2683. PubMed ID: 31017831
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The history of vaccination against cytomegalovirus.
    Plotkin S
    Med Microbiol Immunol; 2015 Jun; 204(3):247-54. PubMed ID: 25791890
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preventing Infection by Human Cytomegalovirus.
    Plotkin SA
    J Infect Dis; 2020 Mar; 221(Suppl 1):S123-S127. PubMed ID: 32134484
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine.
    Starr SE; Glazer JP; Friedman HM; Farquhar JD; Plotkin SA
    J Infect Dis; 1981 Apr; 143(4):585-9. PubMed ID: 6263984
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles.
    Pepperl-Klindworth S; Frankenberg N; Plachter B
    J Clin Virol; 2002 Aug; 25 Suppl 2():S75-85. PubMed ID: 12361759
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire.
    Nastke MD; Herrgen L; Walter S; Wernet D; Rammensee HG; Stevanović S
    Cell Mol Life Sci; 2005 Jan; 62(1):77-86. PubMed ID: 15619009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease.
    Wang D; Fu TM
    Curr Opin Virol; 2014 Jun; 6():13-23. PubMed ID: 24632198
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides.
    Ulivieri C; Citro A; Ivaldi F; Mascolo D; Ghittoni R; Fanigliulo D; Manca F; Baldari CT; Li Pira G; Del Pozzo G
    Immunol Lett; 2008 Aug; 119(1-2):62-70. PubMed ID: 18538862
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.
    Loomis RJ; Lilja AE; Monroe J; Balabanis KA; Brito LA; Palladino G; Franti M; Mandl CW; Barnett SW; Mason PW
    Vaccine; 2013 Jan; 31(6):919-26. PubMed ID: 23246547
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation.
    Ludwig B; Kraus FB; Kipp M; Preiser W; Schwerdtfeger R; Doerr HW; Buxbaum S
    J Clin Virol; 2006 Feb; 35(2):160-6. PubMed ID: 16112610
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bacterial artificial chromosome clones of viruses comprising the towne cytomegalovirus vaccine.
    Cui X; Adler SP; Davison AJ; Smith L; Habib el-SE; McVoy MA
    J Biomed Biotechnol; 2012; 2012():428498. PubMed ID: 22187535
    [TBL] [Abstract][Full Text] [Related]  

  • 74. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection.
    Schleiss MR
    Curr Opin Mol Ther; 2009 Oct; 11(5):572-8. PubMed ID: 19806506
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunisation trials with live attenuated cytomegalovirus TOWNE 125.
    Just M; Buergin-Wolff A; Emoedi G; Hernandez R
    Infection; 1975; 3(2):111-4. PubMed ID: 171221
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.
    Mersseman V; Böhm V; Holtappels R; Deegen P; Wolfrum U; Plachter B; Reyda S
    Med Microbiol Immunol; 2008 Jun; 197(2):97-107. PubMed ID: 18320219
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand.
    Tomić A; Varanasi PR; Golemac M; Malić S; Riese P; Borst EM; Mischak-Weissinger E; Guzmán CA; Krmpotić A; Jonjić S; Messerle M
    PLoS Pathog; 2016 Dec; 12(12):e1006015. PubMed ID: 27907183
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recent approaches and strategies in the generation of antihuman cytomegalovirus vaccines.
    Boppana SB; Britt WJ
    Methods Mol Biol; 2014; 1119():311-48. PubMed ID: 24639230
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus.
    Plotkin SA; Farquhar J; Horberger E
    J Infect Dis; 1976 Nov; 134(5):470-5. PubMed ID: 186541
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
    Wloch MK; Smith LR; Boutsaboualoy S; Reyes L; Han C; Kehler J; Smith HD; Selk L; Nakamura R; Brown JM; Marbury T; Wald A; Rolland A; Kaslow D; Evans T; Boeckh M
    J Infect Dis; 2008 Jun; 197(12):1634-42. PubMed ID: 18444883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.